Education
About Us
Working with TipRanks
Follow Us
Zenas BioPharma, Inc. (ZBIO)
NASDAQ:ZBIO
ZBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.83 - $26.25
Previous CloseN/A
Volume96.53K
Average Volume (3M)192.30K
Market Cap
$849.37M
Enterprise Value$133.40M
Total Cash (Recent Filing)$273.28M
Total Debt (Recent Filing)$1.01M
Price to Earnings (P/E)―
Beta0.78
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.90
Shares Outstanding42,110,313
10 Day Avg. Volume251,935
30 Day Avg. Volume192,296
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.16
Enterprise Value/Revenue8.89
Enterprise Value/Gross Profit8.92
Enterprise Value/Ebitda-0.72
Forecast
1Y Price Target
$33.25Price Target Upside64.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe pivotal Phase 3 INDIGO trial for obexelimab in IgG4-related disease has completed enrollment, highlighting continued progress.
Funding And Financial EndorsementZenas BioPharma has entered into a funding agreement with Royalty Pharma providing up to $300M in cash, indicating a strong endorsement of Zenas BioPharma's potential in the market.
Market DifferentiationObexelimab is a self-administered subcutaneous injection, potentially offering convenience and safety differentiation compared to intravenous treatments like Amgen's Uplizna.
Bears Say
Competitive LandscapeThe competition with CD20-depleting monoclonal antibodies highlights potential challenges in demonstrating the safety/efficacy benefit of obexelimab.
Financial DependencyThe company has indicated that a partnership will likely be needed to advance the MS program, suggesting potential challenges in moving forward independently.
Pipeline RisksThere is a need for favorable readouts to rerate the stock positively after a news-light post-IPO period.
Zenas BioPharma, Inc. News
ZBIO FAQ
What was Zenas BioPharma, Inc.’s price range in the past 12 months?
Zenas BioPharma, Inc. lowest stock price was $5.83 and its highest was $26.25 in the past 12 months.
What is Zenas BioPharma, Inc.’s market cap?
Zenas BioPharma, Inc.’s market cap is $849.37M.
When is Zenas BioPharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zenas BioPharma, Inc.’s earnings last quarter?
Zenas BioPharma, Inc. released its earnings results on May 15, 2025. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$1.134 by $0.334.
Is Zenas BioPharma, Inc. overvalued?
According to Wall Street analysts Zenas BioPharma, Inc.’s price is currently Undervalued.
Does Zenas BioPharma, Inc. pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
What is Zenas BioPharma, Inc.’s EPS estimate?
Zenas BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zenas BioPharma, Inc. have?
Zenas BioPharma, Inc. has 42,110,313 shares outstanding.
What happened to Zenas BioPharma, Inc.’s price movement after its last earnings report?
Zenas BioPharma, Inc. reported an EPS of -$0.8 in its last earnings report, beating expectations of -$1.134. Following the earnings report the stock price went up 6.711%.
Which hedge fund is a major shareholder of Zenas BioPharma, Inc.?
Currently, no hedge funds are holding shares in ZBIO
Zenas BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.25 (64.85% Upside)
$33.25 (64.85% Upside)
Blogger Sentiment
Bullish
ZBIO Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 10.4%
Last 30 Days ▼ 10.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-88.40%
Trailing 12-Months
Asset Growth
46.58%
Trailing 12-Months
Company Description
Zenas BioPharma, Inc.
Zenas BioPharma, Inc. (ZBIO) is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for patients with unmet medical needs. Operating within the biotechnology and pharmaceutical sectors, the company is dedicated to advancing its pipeline of biologics and small molecule drugs aimed at treating complex diseases. Zenas BioPharma leverages cutting-edge technology and scientific expertise to bring novel therapeutics from the lab to the market.
ZBIO Stock 12 Month Forecast
Average Price Target
$33.25
▲(64.85% Upside)
Technical Analysis
Checkpoint Therapeutics
―
Eton Pharmaceuticals
―
Tourmaline Bio
―
Amylyx Pharmaceuticals Inc
―
Rapport Therapeutics, Inc.
―
Ownership Overview
40.40% Insiders
6.67% Mutual Funds
44.77% Other Institutional Investors
6.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---